Curis Lifesciences IPO
UpcomingAlready have an account? Apply now
Curis Lifesciences IPO details
Schedule of Curis Lifesciences
| Issue open date | 07 Nov 2025 |
| Issue close date | 11 Nov 2025 |
| UPI mandate deadline | 11 Nov 2025 (5 PM) |
| Allotment finalization | 12 Nov 2025 |
| Refund initiation | 13 Nov 2025 |
| Share credit | 13 Nov 2025 |
| Listing date | 14 Nov 2025 |
| Mandate end date | 26 Nov 2025 |
| Lock-in end date for anchor investors (50%) | 12 Dec 2025 |
| Lock-in end date for anchor investors (remaining) | 10 Feb 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Curis Lifesciences
Curis Lifesciences Limited began as “M/s Loreto Pharmaceuticals,” a partnership firm founded in 2010, engaged in marketing and trading pharma products. The company specializes in the manufacturing of tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments.
The company operates through three key verticals: loan license manufacturing, contract manufacturing, and direct export under its own brands. Its products are supplied domestically and exported to over 35 countries, including Kenya, Yemen, Nigeria, Myanmar, and Vietnam. With an installed capacity of 138 crore tablets and 15.75 crore capsules annually, Curis has served over 100 customers in loan license and contract manufacturing and is expanding its direct export footprint.
The company’s WHO-GMP certified manufacturing facility in Sanand, Gujarat, is equipped with quality control labs and modern production units. Its clientele includes well-known pharmaceutical brands like J B Chemicals, Troikaa Pharmaceuticals, Express Pharma, and Venus International.
Financials of Curis Lifesciences
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 27.52 |
| Fresh Issue – Proceeds go to the company | 27.52 |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Upgrading of Manufacturing Facilities | 2.44 (8.87%) |
| Construction of Storage Facility | 3.62 (13.16%) |
| Pre-payment/Repayment of Secured Loans | 1.86 (6.76%) |
| Product Registrations in Other Countries | 2.69 (9.78%) |
| Working Capital | 11.25 (40.88%) |
| General Corporate Purposes | 5.66 (20.55%) |
Strengths
- Strong brand recognition through “Mufti”, a leading casual menswear label.
- Wide distribution network across 600+ stores and 1,400+ multi-brand outlets.
- Focused product strategy targeting youthful, urban customers with competitive pricing.
- Asset-light model with third-party manufacturing keeps operating costs low.
- Experienced leadership driving steady growth in sales and profitability.
Risks
- High dependence on third-party manufacturers for product quality and timelines.
- Intense competition from established apparel brands and fast-fashion players.
- Reliance on India’s discretionary spending trends, vulnerable to economic slowdown.
- No long-term contracts with suppliers and distributors may disrupt supply chains.
Allotment Status for Curis Lifesciences
To check your IPO allotment status:
- Visit the MUFG Intime India IPO Application Status page.
- Select the company name from the dropdown menu.
- Select and enter one of the following: PAN, Application Number, DP/Client ID, or Account Number/IFSC.
- Click Submit to view your allotment status.